Corporate News

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that it has signed a contract with Screen4 Ltd (“Screen4”) to provide a testing service using the Mologic ELISA¹ antibody test for COVID-19 from the Company’s in-house testing laboratory in Littleport, Cambridgeshire. 

This follows the launch of the COVID-19 antibody testing service, as announced on 26 January 2021. The contract is for an initial term of three years.

Screen4 is a leading provider of COVID-19 testing services and diagnostic testing services to the aviation, petrochemical, occupational health and consumer markets in the UK and across the Middle east and Far East regions. Screen4 is an Approved Provider under the UK Government General testing and ‘Test to Release’ Scheme in the UK.

Colin King, CEO of Omega, commented: “Following on from setting up and launching our in-house testing service that utilises the Mologic COVID-19 IgG ELISA, I am pleased to be working with Screen4 as our first customer. Screen4 provide a synergistic approach involving health assessment and patient support to their clients.”

¹ ELISA (Enzyme Linked Immuno-Sorbent Assay) tests are one of the most tested and proven laboratory technologies used by the global diagnostic industry and remain the principal reference point from which rapid diagnostics are coordinated, especially serological tests, including tests for COVID-19.

Contacts: